XML 34 R18.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Financial Instruments and Risk Management | 12 Months Ended
--- | ---
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
Financial Instruments And Risk Management | Financial Instruments and Risk ManagementThe Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk. Foreign Currency Risk Management In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations. The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen and Chinese Renminbi for up to eighteen months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings. Net Investment Hedges The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments. The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps. The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:
|  |  |  | Notional Amount Designated as a Net Investment Hedge
(in millions) |  | Principal Amount |  | December 31, 2021 |  | December 31, 2020
Euro |  |  |  |  |  |
2.250% Euro Senior Notes due 2024 |  | € | 1,000.0 |  |  | € | 1,000.0 |  |  | € | 1,000.0 |
3.125% Euro Senior Notes due 2028 |  | 750.0 |  |  | 750.0 |  |  | 750.0 |
2.125% Euro Senior Notes due 2025 |  | 500.0 |  |  | 500.0 |  |  | 500.0 |
0.816% Euro Senior Notes due 2022 |  | 750.0 |  |  | 750.0 |  |  | 750.0 |
1.023% Euro Senior Notes due 2024 |  | 750.0 |  |  | 750.0 |  |  | 750.0 |
1.362% Euro Senior Notes due 2027 |  | 850.0 |  |  | 850.0 |  |  | 850.0 |
1.908% Euro Senior Notes due 2032 |  | 1,250.0 |  |  | 1,250.0 |  |  | 1,250.0 |
Foreign currency forward contracts |  | 105.6 |  |  | — |  |  | 105.6 |
Euro Total |  | € | 5,955.6 |  |  | € | 5,850.0 |  |  | € | 5,955.6 |
Yen |  |  |  |  |  |
YEN Term Loan |  | ¥ | 40,000.0 |  |  | ¥ | 40,000.0 |  |  | ¥ | — |
Yen Total |  | ¥ | 40,000.0 |  |  | ¥ | 40,000.0 |  |  | ¥ | — |
At December 31,2021, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $347.6 million. Interest Rate Risk Management The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings. Cash Flow Hedging Relationships The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations. Fair Value Hedging Relationships The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020. Credit Risk Management The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities. The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:
| Asset Derivatives |  | Liability Derivatives
(In millions) | Balance Sheet Location | December 31, 2021 Fair Value | December 31, 2020 Fair Value |  | Balance Sheet Location | December 31, 2021 Fair Value | December 31, 2020 Fair Value
Derivatives designated as hedges: |  |  |  |  |  |  |
Foreign currency forward contracts | Prepaid expenses & other current assets | $ | 62.0 |  | $ | 28.3 |  |  | Other current liabilities | $ | 4.3 |  | $ | 0.8 |
Total derivatives designated as hedges |  | 62.0 |  | 28.3 |  |  |  | 4.3 |  | 0.8 |
Derivatives not designated as hedges: |  |  |  |  |  |  |
Foreign currency forward contracts | Prepaid expenses & other current assets | 82.6 |  | 90.3 |  | Other current liabilities | 56.7 |  | 102.8
Total derivatives not designated as hedges |  | 82.6 |  | 90.3 |  |  | 56.7 |  | 102.8
Total derivatives |  | $ | 144.6 |  | $ | 118.6 |  |  |  | $ | 61.0 |  | $ | 103.6 |
The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:
|  |  | Amount of Gains/(Losses) Recognized in Earnings |  | Amount of Gain Excluded from the Assessment of Hedge Effectiveness
|  |  | Year Ended December 31, |  | Year Ended December 31,
(In millions) | Location of Gain/(Loss) |  | 2021 | 2020 | 2019 |  | 2021 | 2020 | 2019
Derivative Financial Instruments in Fair Value Hedge Relationships (1) : |  |  |  |  |  |  |  |  |
Interest rate swaps | Interest expense (3) |  | $ | — |  | $ | 22.1 |  | $ | 18.7 |  |  | $ | — |  | $ | — |  | $ | — |
2023 Senior Notes (3.125% coupon) | Interest expense (3) |  | — |  | (22.1) |  | (18.7) |  |  | — |  | — |  | — |
Derivative Financial Instruments in Cash Flow Hedging Relationships : |  |  |  |  |  |  |  |  |
Foreign currency forward contracts | Other expense, net (5) |  | — |  | — |  | — |  |  | — |  | 7.1 |  | — |
Derivative Financial Instruments Not Designated as Hedging Instruments: |  |  |  |  |  |  |  |  |
Foreign currency option and forward contracts | Other expense, net (3) |  | 39.3 |  | (10.1) |  | (17.3) |  |  | — |  | — |  | — |
Total |  |  | $ | 39.3 |  | $ | (10.1) |  | $ | (17.3) |  |  | $ | — |  | $ | 7.1 |  | $ | — |
|  |  | Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives |  | Amount of Gains/(Losses) Reclassified from AOCE into Earnings
|  |  | Year Ended December 31, |  | Year Ended December 31,
(In millions) | Location of Gain/(Loss) |  | 2021 | 2020 | 2019 |  | 2021 | 2020 | 2019
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) : |  |  |  |  |  |  |  |  |
Foreign currency forward contracts | Net sales (4) |  | $ | 45.8 |  | $ | 20.6 |  | $ | 16.6 |  |  | $ | 30.9 |  | $ | 4.8 |  | $ | (0.7) |
Interest rate swaps | Interest expense (4) |  | (3.4) |  | — |  | 3.0 |  |  | (4.3) |  | (4.5) |  | (7.1) |
Derivative Financial Instruments in Net Investment Hedging Relationships: |  |  |  |  |  |  |  |  |
Foreign currency borrowings and forward contracts |  |  | 436.6 |  | (346.4) |  | 56.7 |  |  | — |  | — |  | — |
Total |  |  | $ | 479.0 |  | $ | (325.8) |  | $ | 76.3 |  |  | $ | 26.6 |  | $ | 0.3 |  | $ | (7.8) |
____________ (1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled. (2)At December 31, 2021, the Company expects that approximately $21.0 million of pre-tax net gains on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months. (3)Represents the location of the gain/(loss) recognized in earnings on derivatives. (4)Represents the location of the gain/(loss) reclassified from AOCE into earnings. (5)Represents the location of the gain excluded from the assessment of hedge effectiveness. Fair Value Measurement Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value. Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:
| December 31, 2021
(In millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
Recurring fair value measurements |  |  |  |  |  |  |
Financial Assets
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 50.9 |  |  | $ | — |  |  | $ | — |  |  | $ | 50.9 |
Total cash equivalents | 50.9 |  |  | — |  |  | — |  |  | 50.9 |
Equity securities: |  |  |  |  |  |  |
Exchange traded funds | 50.3 |  |  | — |  |  | — |  |  | 50.3 |
Marketable securities | 0.7 |  |  | — |  |  | — |  |  | 0.7 |
Total equity securities | 51.0 |  |  | — |  |  | — |  |  | 51.0 |
Available-for-sale fixed income investments: |  |  |  |  |  |  |
Corporate bonds | — |  |  | 16.6 |  |  | — |  |  | 16.6 |
U.S. Treasuries | — |  |  | 14.6 |  |  | — |  |  | 14.6 |
Agency mortgage-backed securities | — |  |  | 2.0 |  |  | — |  |  | 2.0 |
Asset backed securities | — |  |  | 4.6 |  |  | — |  |  | 4.6 |
Other | — |  |  | 0.4 |  |  | — |  |  | 0.4 |
Total available-for-sale fixed income investments | — |  |  | 38.2 |  |  | — |  |  | 38.2 |
Foreign exchange derivative assets | — |  |  | 144.6 |  |  | — |  |  | 144.6 |
Total assets at recurring fair value measurement | $ | 101.9 |  |  | $ | 182.8 |  |  | $ | — |  |  | $ | 284.7 |
Financial Liabilities
Foreign exchange derivative liabilities | $ | — |  |  | $ | 61.0 |  |  | $ | — |  |  | $ | 61.0 |
Contingent consideration | — |  |  | — |  |  | 199.7 |  |  | 199.7 |
Total liabilities at recurring fair value measurement | $ | — |  |  | $ | 61.0 |  |  | $ | 199.7 |  |  | $ | 260.7 |
| December 31, 2020
(In millions) | Level 1 |  | Level 2 |  | Level 3 |  | Total
Recurring fair value measurements |  |  |  |  |  |  |
Financial Assets
Cash equivalents: |  |  |  |  |  |  |
Money market funds | $ | 0.9 |  |  | $ | — |  |  | $ | — |  |  | $ | 0.9 |
Total cash equivalents | 0.9 |  |  | — |  |  | — |  |  | 0.9 |
Equity securities: |  |  |  |  |  |  |
Exchange traded funds | 45.1 |  |  | — |  |  | — |  |  | 45.1 |
Marketable securities | 0.7 |  |  | — |  |  | — |  |  | 0.7 |
Total equity securities | 45.8 |  |  | — |  |  | — |  |  | 45.8 |
Available-for-sale fixed income investments: |  |  |  |  |  |  |
Corporate bonds | — |  |  | 17.8 |  |  | — |  |  | 17.8 |
U.S. Treasuries | — |  |  | 14.4 |  |  | — |  |  | 14.4 |
Agency mortgage-backed securities | — |  |  | 1.9 |  |  | — |  |  | 1.9 |
Asset backed securities | — |  |  | 4.6 |  |  | — |  |  | 4.6 |
Other | — |  |  | 0.4 |  |  | — |  |  | 0.4 |
Total available-for-sale fixed income investments | — |  |  | 39.1 |  |  | — |  |  | 39.1 |
Foreign exchange derivative assets | — |  |  | 118.6 |  |  | — |  |  | 118.6 |
Total assets at recurring fair value measurement | $ | 46.7 |  |  | $ | 157.7 |  |  | $ | — |  |  | $ | 204.4 |
Financial Liabilities
Foreign exchange derivative liabilities | $ | — |  |  | $ | 103.6 |  |  | $ | — |  |  | $ | 103.6 |
Contingent consideration | — |  |  | — |  |  | 223.6 |  |  | 223.6 |
Total liabilities at recurring fair value measurement | $ | — |  |  | $ | 103.6 |  |  | $ | 223.6 |  |  | $ | 327.2 |
For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2021 and 2020, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities: •Cash equivalents — valued at observable net asset value prices. •Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations. •Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in other expense, net, in the consolidated statements of operations. •Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity. •Interest rate swap derivative assets and liabilities — valued using the LIBOR/EURIBOR yield curves at the reporting date. Counterparties to these contracts are highly rated financial institutions. •Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions. Contingent Consideration In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair® Diskus incorporating Pfizer’s respiratory delivery platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela® Inhub® occurred in February 2019. As of December 31, 2021, the Company has a contingent consideration liability of $177.8 million related to the respiratory delivery platform. The fair value measurement of contingent consideration is determined using Level 3 inputs. The Company’s contingent consideration represents a component of the total purchase consideration for Pfizer’s respiratory delivery platform and certain other acquisitions. The measurement is calculated using unobservable inputs based on the Company’s own assumptions primarily related to the probability and timing of future development and commercial milestones and future profit-sharing payments which are discounted using a market rate of return. At December 31, 2021 and 2020, discount rates ranging from 8.0% to 10.5% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liability. A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2019 to December 31, 2021 is as follows:
(In millions) | Current Portion (1) |  | Long-Term Portion (2) |  | Total Contingent Consideration
Balance at December 31, 2019 | $ | 120.4 |  |  | $ | 130.3 |  |  | $ | 250.7 |
Payments | (111.8) |  |  | — |  |  | (111.8) |
Reclassifications | 58.1 |  |  | (58.1) |  |  | — |
Accretion | — |  |  | 11.6 |  |  | 11.6 |
Fair value loss (3) | 33.8 |  |  | 39.3 |  |  | 73.1 |
Balance at December 31, 2020 | $ | 100.5 |  |  | $ | 123.1 |  |  | $ | 223.6 |
Payments | (83.2) |  |  | — |  |  | (83.2) |
Reclassifications | 49.4 |  |  | (49.4) |  |  | — |
Accretion | — |  |  | 9.0 |  |  | 9.0 |
Fair value loss (3) | — |  |  | 50.3 |  |  | 50.3 |
Balance at December 31, 2021 | $ | 66.7 |  |  | $ | 133.0 |  |  | $ | 199.7 |
____________ (1)Included in other current liabilities in the consolidated balance sheets. (2)Included in other long-term obligations in the consolidated balance sheets. (3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations. The Company expects to incur approximately $6 million to $8 million of non-cash accretion expense related to the increase in the net present value of the contingent consideration liabilities in 2022. Although the Company has not elected the fair value option for financial assets and liabilities, any future transacted financial asset or liability will be evaluated for the fair value election. Available-for-Sale Securities The amortized cost and estimated fair value of available-for-sale fixed income securities, included in prepaid expenses and other current assets, were as follows:
(In millions) | Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Value
December 31, 2021 |  |  |  |  |  |  |
Debt securities | $ | 38.1 |  |  | $ | 0.1 |  |  | $ | — |  |  | $ | 38.2 |
| $ | 38.1 |  |  | $ | 0.1 |  |  | $ | — |  |  | $ | 38.2 |
December 31, 2020 |  |  |  |  |  |  |
Debt securities | $ | 37.5 |  |  | $ | 1.6 |  |  | $ | — |  |  | $ | 39.1 |
| $ | 37.5 |  |  | $ | 1.6 |  |  | $ | — |  |  | $ | 39.1 |
Maturities of available-for-sale debt securities at fair value as of December 31, 2021, were as follows:
(In millions) |
Mature within one year | $ | 1.2 |
Mature in one to five years | 19.7 |
Mature in five years and later | 17.3 |
| $ | 38.2 |

X
- References No definition available. + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration